Facebook
Twitter
LinkedIn
Forward2023 Summit on Cancer Health Disparities- Recorded Webcast
This accredited continuing education activity “2023 Summit on Cancer Health Disparities”, was recorded from the live course held on 04/28/23-04/30/23
If you participated in the live course titled - 2023 Summit on Cancer Health Disparities: Reframing and Addressing Barriers to Adoption of Precision Oncology (SCHD23) on 04/28/23-04/30/23 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This was recorded from the live course on 04/28/23-04/30/23. However, you may enroll in this activity to review the contents.
SCHD23 is an accredited continuing education activity (CME activity) that fosters collaborative interdisciplinary interactions and partnerships to stimulate the development of new research and clinical practices that reduce cancer health disparities and improve outcomes of the diverse patient population.
REGISTRATION FEES:
This activity is free for all.
Target Audience
- Oncologist and Hematologists
- Oncology and Hematology Nurse Practitioners
- Oncology and Hematology Physician Assistants
- Oncology and Hematology Nurses
- Oncology and Hematology Pharmacists
- Oncology and Hematology Fellows/Residents
- Oncology and Hematology Researchers
- Others interested in cancer disparities
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Identify drivers of cancer health disparities and review their impact on patients along the cancer continuum.
- State the financial and physical barriers and review strategies to navigate these factors to optimize the management of patients with cancer.
- Incorporate evidence-based strategies to minimize the impact of specific drivers of inequity in the management of patients with cancer.
- Review barriers to using precision-guided cancer care and discuss evidence-based strategies to navigate these barriers to incorporate the new standards of care in managing patients with cancer.
- Describe challenges and develop novel approaches to improve the participation of underrepresented communities in clinical trials.
This educational activity features recorded videos from the live course titled - 2023 Summit on Cancer Health Disparities held April 28-30th, 2023
The videos are placed in the following order. Feel free to view the content that is relevant to you.
Participants should claim continuing education credits to the extent of their participation.
Day 1 - April 28, 2023
SESSION 1 - Clinical trials
Chair: Dr. Hala Borno
15 minutes: Rising tide of biomarker selected studies - how genomic testing is key to unlocking inequities in oncology clinical trial access - Dr. Hiba Khan
15 minutes: Advanced imaging and stage migration - how finding more diseases may lead to more opportunities - Dr. Curtiland Deville
12 minutes: Applying a social determinant of health framework to address clinical trial inequities - Dr. Samuel Washington
15 minutes: Q&A/Panel
SESSION 2 - Immunotherapy and cellular therapy
Chair: Dr. Shailender Bhatia
15 minutes: The tsunami of cellular immunotherapies is coming: How can we prepare for equitable access? - Dr. Rahul Banerjee
15 minutes: Immune checkpoint inhibitors: Innovative dosing strategies to expand access globally - Dr. Lisa Tachiki
30 minutes: Q&A/Panel - Session speakers + Dr. Krishna Komanduri, Dr. Hiba Khan
SESSION 3 - Novel therapies in cancer
Chair: Dr. Mark Pegram
30 minutes: Keynote lecture - Dr. Jerry Radich
30 minutes: Panel discussion/Q&A - Dr. Parameswaran Hari, Dr. Lidia Schapira, & Dr. Manali Patel
SESSION 4 - Access to Cancer Care in LMIC - Navigating Current Challenges
Chair: Dr. Aparna Parikh
25 minutes: Oncology Nurse Capacity Building Program in a Low-Income Country Setting - Lori Buswell, MSN, ANP-C & Olivier Habimana, RN
12 minutes: The Nursing Experience in Botswana: Leading Patient-Centered Care - Lorraine Drapek, DNP, FNP-BC, AOCNP
15 minutes: Panel/Q&A
15 minutes: Equitable Partnerships in Global Oncology: Best Practice Examples of a AMCs/LMICs partnership - Dr. Katherine Van Loon
15 minutes: Equitable Partnerships in Global Oncology: Best Practice Examples of a AMCs/LMICs partnership - Dr. Erika Ruiz-Garcia
10 minutes: Panel/Q&A
SESSION 5 - Addressing Disparities in Diagnostics, Artificial Intelligence & Machine Learning
Chair: Dr. Ronald Balassanian & Dr. Dan Milner
18 minutes: See, Test & Treat Programs in Domestic Setting - Dr. Eva M. Wojcik
18 minutes: Breast fine needle aspiration (FNA) biopsy in battling diagnostic barriers to cancer care - Dr. Asteria Kimambo
16 minutes: Applied machine learning to improve communication and end-of-life care for patients with cancer - Dr. Christopher Manz
15 minutes: Making a smarter oncology clinic: how can artificial intelligence identify and reduce disparities in care? - Dr. Julian Hong
20 minutes: Panel discussion - Dr. Wojcik, Dr. Kimambo, Dr. Manz, Dr. Hong, Dr. Milner, & Dr. Ronald Balassanian
Career in Oncology - Success Lounge
Chair: Dr. Michael Schweizer & Dr. Jerry Radich
60 minutes: Career in Oncology- Dr. Katherine Van Loon, Dr. Tanya Wahl, Dr. Narjust Florez, Dr. Andrea Veatch
DAY 2 - APRIL 29, 2023
SESSION 6 - LGBTQI, Young Adults
Chair: Dr. David Aboulafia
20 minutes: Supportive care among people living with HIV and cancer in the US - Dr. Jessica Islam
15 minutes: Engaging LGBTQI+ communities in clinical trials - Michael Louella, BS
17 minutes: Engaging resource-constrained countries in research trials of HIV and Cancer: Lessons from Uganda and the AIDS Malignancy Consortium - Dr. Warren Phipps
7 minutes: Panel/Q&A
SESSION 7 - Plenary session
Chairs: Dr. Hannah Linden & Dr. Ana Maria Lopez
30 minutes: Precision Medicine in Low and Middle-Income Countries - Dr. Julie Gralow
23 minutes: Panel/Q&A - LaToya Williams, MBA, Dr. Katherine Van Loon, Dr. Marianne Dubard-Gault
SESSION 8 - Surgical Oncology
Chair: Dr. Evan Glazer
19 minutes: Understanding disparities in palliative care of the cancer surgery patient - Dr. Bridget Fahy
12 minutes: Identifying opportunities to address disparities in gastrointestinal surgical oncology - Dr. Ambria Moten
15 minutes: Rural/urban disparities in peri-operative systemic therapy in patients with breast and cutaneous malignancies - Dr. Cristina O'Donoghue
19 minutes: Panel/Q&A
SESSION 9 - Radiation Oncology
Chair: Dr. Lia Moriguchi Halasz
17 minutes: Cancer Equity Research: Priorities for a New Era - Dr. Gita Suneja
15 minutes: Disparities in Access to Radiation Oncology Facilities by Race and Ethnicity in Washington State and United States - Dr. Solmaz Amiri
13 minutes: Cancer Equity Globally: the Radiation Oncology Perspective - Dr. Benjamin Li
18 minutes: Global Expertise in Medical Physics - Dr. Afua Yorke
SESSION 10 - Private practice and academia
Chair: Dr. Ulka Vaishampayan
25 minutes: Improving Access: A Veterans Health System Perspective - Dr. Julie Graff
30 minutes: The Access and Quality of Palliative Care within Cancer Care Community - Dr. Ishwaria Subbiah
18 minutes: Panel discussion: Improving Cancer Care in the Academia and Community: Working Together towards a common goal! - Dr. Joseph Rosales, Dr. Julie Graff, Dr. Paul Monk, Dr. Ishwaria Subbiah, & Dr. Scott Tykodi
SESSION 11 - Career in Cancer Health Disparities - training and funding opportunities
Chair: Dr. Ana Maria Lopez
20 minutes: Keynote lecture - Dr. Nelson Aguila
30 minutes: Panel discussion - Dr. Nelson Aguila, Anna Marsden, MBA, Reuben Cano, & Dr. Candace Chow
SESSION 12 - Current oncology workforce (Avoiding burnout, optimizing patient care)
Chair: Dr. Hannah Linden
24 minutes: What’s Moral Distress got to do with it? Equity and Burnout - Dr. Claudia Finkelstein
25 minutes: Panel/Q&A- Dr. Natalie Uy & Dr. Lynn Symonds
DAY 3 - APRIL 30, 2023
35 minutes: Career Reflection - Dr. Edith Mitchell
SESSION 13 - Screening and Early detection
Chair: Dr. Robert Smith
25 minutes: Examining Implicit Bias and Health Disparities through the Cancer Screening Lens - Dr. Shana O. Ntiri
18 minutes: The use of prediction models to reduce racial disparities in lung cancer Screening eligibility - Dr. Rebecca Landy
24 minutes: Computable Practice Guidelines and Clinical Decision Support Can Help Address Health Disparities in Cervical Cancer Screening and Management - Ginny Meadows, MSHI, RN-BC
30 minutes: Applying precision approaches to address disparities in follow-up colonoscopy uptake - Dr. Gloria Coronado
FACULTY
COURSE DIRECTOR(S)
David Aboulafia, MD has no relevant financial relationships to disclose at this time.
Hannah Linden, MD FACP has a financial relationship (Grant Or Contract) with Sanofi financial relationship (Grant Or Contract) with Veru Pharmaceuticals; financial relationship (Professional Services) with Gillead ; financial relationship (Grant Or Contract) with Tolmar; financial relationship (Grant Or Contract) with GE Healthcare .
Ana Maria Lopez, MD, MPH has no relevant financial relationships to disclose at this time.
Aparna Parikh, MD has a financial relationship (Grant Or Contract) with Takeda; financial relationship (Grant Or Contract) with Genentech; financial relationship (Other) with Eli Lilly ; financial relationship (Other) with Checkmate Pharmaceuticals; financial relationship (Other) with Roche; financial relationship (Grant Or Contract) with Novartis; financial relationship (Other) with Roche; financial relationship (Other) with Natera; financial relationship (Other) with Abbvie; financial relationship (Grant Or Contract) with Plexxicon; financial relationship (Grant Or Contract) with Mirati; financial relationship (Grant Or Contract) with Daiichi Sankyo; financial relationship (Other) with Pfizer ; financial relationship (Other) with Biofidelity; financial relationship (Other) with Guardant; financial relationship (Grant Or Contract) with PMV Pharmaceuticals; financial relationship (Grant Or Contract) with BMS; financial relationship (Grant Or Contract) with Natera; financial relationship (Other) with C2i genomics; financial relationship (Other) with Inivata; financial relationship (Other) with FMI; financial relationship (Grant Or Contract) with PureTech.
Binay Shah, MD, MHA has no relevant financial relationships to disclose at this time.
Siddhartha Yadav, Siddhartha Yadav, MD, FACP has no relevant financial relationships to disclose at this time.
MODERATOR(S)
David Aboulafia, MD has no relevant financial relationships to disclose at this time.
Ron Balassanian, MD has a financial relationship (Stock) with Cerus corp; financial relationship (Professional Services) with Genentech.
Shailender Bhatia, MD has a financial relationship (Grant Or Contract) with Incyte; financial relationship (Grant Or Contract) with Nektar Therapeutics; financial relationship (Professional Services) with Regeneron/Sanofi; financial relationship (Grant Or Contract) with 4SC; financial relationship (Grant Or Contract) with Regeneron (fka Checkmate Pharmaceuticals); financial relationship (Grant Or Contract) with Immune Design; financial relationship (Grant Or Contract) with NantKwest; financial relationship (Grant Or Contract) with Xencor; financial relationship (Grant Or Contract) with Bristol Meyers Squibb; financial relationship (Grant Or Contract) with Exicure; financial relationship (Grant Or Contract) with Merck; financial relationship (Grant Or Contract) with Trisalus Life Sciences; financial relationship (Grant Or Contract) with Amphivena; financial relationship (Grant Or Contract) with Kuni Foundation; financial relationship (Grant Or Contract) with Novartis; financial relationship (Grant Or Contract) with Agenus; financial relationship (Grant Or Contract) with EMD Serono.
Hala Borno, M.D has a financial relationship (Stock) with Trial Library, Inc; financial relationship (Stock) with Collective Health, Inc; financial relationship (Stock) with Waymark, Inc.
Evan Glazer, MD, PhD, FACS, FSSO has no relevant financial relationships to disclose at this time.
Lia Halasz, MD has a financial relationship (Grant Or Contract) with Biomimetix.
Hannah Linden, MD FACP has a financial relationship (Grant Or Contract) with Veru Pharmaceuticals; financial relationship (Professional Services) with Gillead ; financial relationship (Grant Or Contract) with Tolmar; financial relationship (Grant Or Contract) with GE Healthcare ; financial relationship (Grant Or Contract) with Sanofi.
Ana Maria Lopez, MD, MPH has no relevant financial relationships to disclose at this time.
Danny Milner, Jr, MD, MSc, MBA has no relevant financial relationships to disclose at this time.
Aparna Parikh, MD has a financial relationship (Other) with Pfizer ; financial relationship (Other) with Biofidelity; financial relationship (Other) with Guardant; financial relationship (Grant Or Contract) with PMV Pharmaceuticals; financial relationship (Grant Or Contract) with Mirati; financial relationship (Grant Or Contract) with Daiichi Sankyo; financial relationship (Other) with C2i genomics; financial relationship (Other) with Inivata; financial relationship (Other) with FMI; financial relationship (Grant Or Contract) with PureTech; financial relationship (Grant Or Contract) with BMS; financial relationship (Grant Or Contract) with Natera; financial relationship (Other) with Eli Lilly ; financial relationship (Other) with Checkmate Pharmaceuticals; financial relationship (Other) with Roche; financial relationship (Grant Or Contract) with Takeda; financial relationship (Grant Or Contract) with Genentech; financial relationship (Other) with Roche; financial relationship (Other) with Natera; financial relationship (Other) with Abbvie; financial relationship (Grant Or Contract) with Plexxicon; financial relationship (Grant Or Contract) with Novartis.
Mark Pegram, MD has no relevant financial relationships to disclose at this time.
jerald radich has a financial relationship (Other) with Cepheid; financial relationship (Other) with NuProbe; financial relationship (Other) with Novartis.
Michael Schweizer, MD has a financial relationship (Independent contractor) with Pharmain; financial relationship (Independent contractor) with AstraZeneca; financial relationship (Independent contractor) with Sanofi.
Robert Smith, PhD has no relevant financial relationships to disclose at this time.
Ulka Vaishampayan, MD has a financial relationship (Professional Services) with Exelixis; financial relationship (Professional Services) with Merck;financial relationship (Professional Services) with sanofi; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Bayer; financial relationship (Professional Services) with Pfizer.
PLANNER(S)
Umang Swami, MD, MS has a financial relationship (Other) with Exelixis; financial relationship (Other) with Astellas;financial relationship (Other) with Seattle Genetics.
Siddhartha Yadav, Siddhartha Yadav, MD, FACP has no relevant financial relationships to disclose at this time.
SPEAKER(S)
H. Aguila, Doctor of Veterinary Medicine has no relevant financial relationships to disclose at this time.
Solmaz Amiri, DDes, Msc has no relevant financial relationships to disclose at this time.
Linda Armstrong, Panel Speaker has a financial relationship (Employment) with Novartis; financial relationship (Professional Services) with iBio Inc; financial relationship (Professional Services) with Upstream Bio.
Rahul Banerjee, MD, FACP has a financial relationship (Grant Or Contract) with Clinical Care Options; financial relationship (Independent contractor) with Guidepoint Global; financial relationship (Grant Or Contract) with Pack Health; financial relationship (Grant Or Contract) with Curio Science; financial relationship (Independent contractor) with Sanofi Pasteur; financial relationship (Independent contractor) with Janssen Oncology; financial relationship (Independent contractor) with SparkCures; financial relationship (Independent contractor) with Genentech/Roche; financial relationship (Grant Or Contract) with i3 Health; financial relationship (Independent contractor) with Clearview Healthcare Partners.
Lori Buswell, MSN, ANP-C has no relevant financial relationships to disclose at this time.
Reuben Ryan Cano has no relevant financial relationships to disclose at this time.
Candace Chow, PhD has no relevant financial relationships to disclose at this time.
Gloria Coronado, PhD has a financial relationship (Professional Services) with Exact Sciences; financial relationship (Grant Or Contract) with Guardant Health.
Curtiland Deville, MD has no relevant financial relationships to disclose at this time.
Lorraine Drapek, DNP FNP-BC AOCNP has no relevant financial relationships to disclose at this time.
Marianne Dubard-Gault, MD, MS has no relevant financial relationships to disclose at this time.
Bridget Fahy has a financial relationship (Stock) with Repligen Corp; financial relationship (Stock) with Moderna; financial relationship (Stock) with Guardant Health, inc; financial relationship (Stock) with HCA Healthcare, Inc; financial relationship (Stock) with Editas Medicine, Inc; financial relationship (Stock) with Masimo Corp; financial relationship (Stock) with Globus Medical, Inc; financial relationship (Stock) with Teladoc Health Inc; financial relationship (Stock) with Intuitive Surgical, Inc; financial relationship (Stock) with Biogen, Inc; financial relationship (Stock) with Shockwave Medical, Inc; financial relationship (Stock) with Bristol-Myers Squibb, Co; financial relationship (Stock) with ResMed Inc; financial relationship (Stock) with Seagen, Inc; financial relationship (Stock) with Neurocrine Biosciences; financial relationship (Stock) with GoodRx Holdings Inc; financial relationship (Stock) with United Health Group; financial relationship (Stock) with Veeva Systems Inc; financial relationship (Stock) with STAAR Surgical Co; financial relationship (Stock) with Fulgent Genetics, Inc; financial relationship (Stock) with DexCom, Inc; financial relationship (Stock) with Align Technology, Inc.
Claudia Finkelstein, MDCM has no relevant financial relationships to disclose at this time.
Narjust Florez, Associate Director of Cancer Care Equity Program, Thoracic Medical Oncologist has a financial relationship (Professional Services) with DSI; financial relationship (Professional Services) with Janssen; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Pfizer; financial relationship (Professional Services) with Merck; financial relationship (Professional Services) with Astrazeneca; financial relationship (Professional Services) with Neogenomics.
Julie Graff, MD has no relevant financial relationships to disclose at this time.
Julie Gralow, MD has no relevant financial relationships to disclose at this time.
Olivier Habimana, RN, BScN has no relevant financial relationships to disclose at this time.
PARAMESWARAN HARI, MD has a financial relationship (Employment) with Iovance Biotherapeutics.
Julian Hong has no relevant financial relationships to disclose at this time.
Jessica Islam, PhD, MPH has no relevant financial relationships to disclose at this time.
Hiba Khan, MD, MPH has no relevant financial relationships to disclose at this time.
Asteria Kimambo, MD, MMED, Anatomical Pathologist has no relevant financial relationships to disclose at this time.
Krishna Komanduri, MD has a financial relationship (Independent contractor) with Iovance; financial relationship (Independent contractor) with Janssen; financial relationship (Independent contractor) with Novartis; financial relationship (Independent contractor) with Cargo Therapeutics; financial relationship (Independent contractor) with Avacta Therapeutics; financial relationship (Independent contractor) with CRISPR Therapeutics; financial relationship (Independent contractor) with Roche; financial relationship (Independent contractor) with Optum Health; financial relationship (Independent contractor) with Incyte.
Rebecca Landy, PhD has no relevant financial relationships to disclose at this time.
Benjamin Li, MD, MBA has no relevant financial relationships to disclose at this time.
Michael Louella, BS has no relevant financial relationships to disclose at this time.
Christopher Manz, MD MSHP has no relevant financial relationships to disclose at this time.
Anna Marsden has no relevant financial relationships to disclose at this time.
Ginny Meadows, MSHI, RN-BC has no relevant financial relationships to disclose at this time.
Edith Mitchell, MD, MACP, FCCP, FRCP has a financial relationship (Professional Services) with SEMA4; financial relationship (Grant Or Contract) with Genentech; financial relationship (Professional Services) with Amgen; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with Bristol, Myers, Squibb; financial relationship (Professional Services) with Corvus; financial relationship (Employment) with Thomas Jefferson University; financial relationship (Professional Services) with Astellas; financial relationship (Grant Or Contract) with Sanofi.
Paul Monk has no relevant financial relationships to disclose at this time.
Ambria Moten, MD, MS has no relevant financial relationships to disclose at this time.
Shana Ntiri, Shana O. Ntiri, MD, MPH, FAAFP has no relevant financial relationships to disclose at this time.
Cristina ODonoghue, MD, MPH has no relevant financial relationships to disclose at this time.
Sydney Osborne has a financial relationship (Employment) with Seagen Inc. .
Manali Patel, MD, MPH, MS has no relevant financial relationships to disclose at this time.
Warren Phipps has no relevant financial relationships to disclose at this time.
Joseph Rosales, MD has no relevant financial relationships to disclose at this time.
Erika Ruiz Garcia, MD, MSc has a financial relationship (Other) with BMS; financial relationship (Other) with AMGEN; financial relationship (Other) with ROCHE/Genentech; financial relationship (Other) with BAYER.
Lidia Schapira, Professor of Medicine has a financial relationship (Independent contractor) with Blue Note Therapeutics.
Ishwaria Subbiah has no relevant financial relationships to disclose at this time.
Gita Suneja, MD, MSHP has no relevant financial relationships to disclose at this time.
Lynn Symonds has no relevant financial relationships to disclose at this time.
Lisa Tachiki, MD has no relevant financial relationships to disclose at this time.
Scott Tykodi, MD, PhD has a financial relationship (Grant Or Contract) with Exelixis; financial relationship (Professional Services) with FirstWord; financial relationship (Grant Or Contract) with Bristol Myers Squibb; financial relationship (Professional Services) with Targeted Oncology; financial relationship (Grant Or Contract) with AVEO Oncology; financial relationship (Professional Services) with Bristol Myers Squibb; financial relationship (Grant Or Contract) with Merck; financial relationship (Grant Or Contract) with Pfizer; financial relationship (Professional Services) with Exelixis.
Natalie Uy, MD has no relevant financial relationships to disclose at this time.
Katherine Van Loon, MD, MPH has no relevant financial relationships to disclose at this time.
Andrea Veatch, MD has no relevant financial relationships to disclose at this time.
Tanya Wahl, Medical Oncologist, Medical Director Providence Swedish Cancer Institute Issaquah has no relevant financial relationships to disclose at this time.
Samuel Washington has no relevant financial relationships to disclose at this time.
LaToya Williams, MBA has no relevant financial relationships to disclose at this time.
Eva Wojcik has no relevant financial relationships to disclose at this time.
Afua Yorke, PhD has no relevant financial relationships to disclose at this time.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This activity is supported by an independent medical education grant from the following companies:
- Novocure, Inc.
- Exact Sciences
- Gilead Sciences
- Pfizer
Important Information about Claiming CME for this activity:
If you participated in the live course titled - 2023 Summit on Cancer Health Disparities: Reframing and Addressing Barriers to Adoption of Precision Oncology (SCHD23) on 04/28/23-04/30/23 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This was recorded from the live course on 04/28/23-04/30/23.
Available Credit
- 16.00 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 16.00 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 16.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 16.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 16.00 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 16.00 Contact Hours.